INSM News and Press, Insmed Inc. From 09/08/23

2023-09-08 14:09:00 ET Shares of Insmed (NASDAQ: INSM) were up more than 17% for the week as of 10:30 a.m. ET on Friday, according to data provided by S&P Global Market Intelligence . The healthcare company closed last week at $22.64, then rose to a 52-week high of $27.1...

Insmed To Present at the Morgan Stanley 21st Annual Global Healthcare Conference PR Newswire BRIDGEWATER, N.J. , Sept. 6, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients wi...

2023-09-05 11:52:52 ET Shares of Insmed (NASDAQ: INSM) were soaring 17.1% higher as of 11:27 a.m. ET on Tuesday. The big gain came after the company announced positive top-line results from its late-stage Arise clinical study evaluating the antibiotic drug Arikayce in treating patie...

Avalon GloboCare Corp ., (NASDAQ: ALBT) a developer of innovative precision diagnostics and provider of clinical laboratory services just announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Publication for U.S. Patent No. 11,555,060, titled “QTY Fc...

2023-09-05 08:42:44 ET Insmed Incorporated ( NASDAQ: INSM ) added ~7% pre-market Tuesday after announcing that a Phase 3 trial for its antibiotic Arikayce reached the main goal in adults with a type of bacterial lung infection. The Phase 3b placebo-controlled trial involved ...

INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG DISEASE CAUSED BY MAC PR Newswire — QOL-B Respiratory Domain Shown to Work Effectively as Patient-Reported Outcom...

With a rising prevalence of chronic diseases, we’re starting to see higher demand for clinical lab services. That being said, it’s no surprise that, according to Market.Us, the global market for clinical laboratory services is projected to grow from $213 billion in 2022 to a stagger...

2023-08-06 00:23:02 ET Insmed Incorporated (INSM) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Bryan Dunn - Head, IR William Lewis - Chair & CEO Sara Bonstein - CFO Martina Flammer - Chief Medical Officer Conferenc...

2023-08-03 07:39:48 ET Insmed press release ( NASDAQ: INSM ): Q2 GAAP EPS of -$1.78 misses by $0.65 . Revenue of $77.2M (+18.4% Y/Y) beats by $6.97M . Company Raises Full-Year 2023 Guidance Range for Global ARIKAYCE Revenues to $295 Million to $3...

Insmed Reports Second-Quarter 2023 Financial Results and Provides Business Update PR Newswire -- ARIKAYCE ® (amikacin liposome inhalation suspension) Total Revenue of $77.2 Million for the Second Quarter of 2023 Reflects Highest Quarter of Sales Since Launch ...